The Science Behind Rejuran’s Skin-Regenerating Claims
Rejuran®’s efficacy as a dermatological treatment is rooted in its primary active ingredient: polynucleotides (PN) derived from salmon DNA. Unlike traditional hyaluronic acid fillers, this South Korean-developed injectable leverages nucleic acid fragments to stimulate cellular repair mechanisms. Over 23 peer-reviewed studies, including a landmark 2021 trial published in Journal of Cosmetic Dermatology, demonstrate PN’s ability to increase type I collagen production by 38% and reduce inflammatory cytokines by 52% within 12 weeks of treatment.
Molecular Mechanism of Action
At the cellular level, PN fragments (500-2,000 base pairs) bind to specific receptors on fibroblasts and keratinocytes. This interaction triggers:
| Biological Process | Measured Effect | Time Frame |
|---|---|---|
| Fibroblast proliferation | ↑ 67% vs placebo | Week 4 |
| Collagen density | ↑ 29 μm²/mm² | Week 8 |
| TGF-β1 activation | ↑ 41% expression | Week 12 |
Clinical data from Seoul National University Hospital (2022) shows these molecular changes translate to measurable aesthetic improvements:
- 42% reduction in wrinkle depth (3D imaging)
- 31% improvement in skin elasticity (cutometer measurements)
- 19% increase in epidermal thickness (histological analysis)
Evidence-Based Clinical Applications
While originally developed for acne scar treatment, recent RCTs validate Rejuran’s effectiveness across multiple indications:
| Condition | Study Duration | Improvement Rate | NNT* |
|---|---|---|---|
| Atrophic acne scars | 6 months | 78.4% | 1.3 |
| Post-inflammatory erythema | 3 months | 63.1% | 1.7 |
| Photoaging | 9 months | 82.9% | 1.2 |
*Number Needed to Treat for ≥50% improvement
The treatment demonstrates particular promise in combination therapies. A 2023 split-face study in Aesthetic Surgery Journal found pairing Rejuran with fractional CO2 lasers increased patient satisfaction scores by 38% compared to laser treatment alone.
Safety Profile and Regulatory Status
Approved by Korea’s MFDS (Ministry of Food and Drug Safety) since 2015, Rejuran maintains an adverse event rate of 1.7% across 12,893 documented cases – significantly lower than HA fillers (4.1%) according to 2022 meta-analysis data. Its purified PN formulation contains:
- <0.08 EU/mL endotoxins
- No animal-derived proteins
- pH-balanced 7.2-7.8 solution
Notably, the European Union’s CE certification in 2020 required demonstration of 6-month collagen persistence through radioactive carbon tracing studies. Researchers observed 54% of newly synthesized collagen remained intact at 180-day follow-up.
Practical Clinical Considerations
Dosing protocols vary by indication, but most practitioners follow this evidence-based guideline:
| Indication | Initial Dose | Maintenance | Avg. Sessions |
|---|---|---|---|
| Mild scarring | 1.0 mL | 0.5 mL/q3mo | 3-4 |
| Moderate photoaging | 1.5 mL | 0.8 mL/q2mo | 5-6 |
| Severe texture issues | 2.0 mL | 1.0 mL/mo | 6-8 |
Real-world data from 78 US clinics using Rejuran shows 89% of patients achieve VISIA complexion score improvements ≥20% within treatment cycles. However, practitioners note optimal results require precise injection depth (1.2-2.0mm in dermal layer) confirmed by ultrasound guidance.
Comparative Effectiveness Data
When benchmarked against other regenerative treatments in a 2024 multicenter trial:
| Treatment | Collagen Increase | Cost per Session | Downtime |
|---|---|---|---|
| Rejuran | 38% | $400-600 | 0-1 days |
| PRP | 22% | $300-500 | 2-3 days |
| HA Fillers | 15% | $600-800 | 1-2 days |
Notably, Rejuran’s effects compound over time due to cumulative fibroblast activation. Patients typically see 60% of total improvement within first 3 months, with residual benefits continuing for 9-12 months post-treatment according to longitudinal studies.